Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B2 | P37059 | 3/20 | 0.67 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.57 |
| ▸ | CCR9 | P51686 | 14/20 | 0.56 |
| ▸ | CCR2 | P41597 | 2/20 | 0.52 |
| ▸ | FBP1 | P09467 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2962212 | 0.90 | HSD17B2 (0.63) | HSD17B2SLC22A12CCR9CCR2 | |
| SCHEMBL4650211 | 0.87 | SLC22A12 (0.63) | HSD17B2SLC22A12CCR9CCR2 | |
| SCHEMBL4651332 | 0.86 | HSD17B2 (0.66) | HSD17B2CCR9 | |
| SCHEMBL4649684 | 0.85 | SLC22A12 (0.54) | SLC22A12CCR9CCR2 | |
| SCHEMBL4649581 | 0.81 | HSD17B2 (0.63) | HSD17B2SLC22A12CCR9 | |
| SCHEMBL1130076 | 0.81 | HSD17B2 (0.64) | HSD17B2CCR9CCR2 | |
| SCHEMBL26537094 | 0.79 | SLC22A12 (0.57) | SLC22A12CCR9FBP1 | |
| SCHEMBL2970692 | 0.77 | HSD17B2 (0.67) | HSD17B2CCR9CCR2 | |
| SCHEMBL2968297 | 0.77 | HSD17B2 (0.67) | HSD17B2CCR9CCR2 | |
| SCHEMBL2616470 | 0.77 | HSD17B2 (0.67) | HSD17B2CCR9CCR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080275114-A1 | Inhibitors of Ccr9 Activity | NOVARTIS AG (CH) | 2008-11-06 | — | — | US | claimed |
| EP-1966131-A1 | INHIBITORS OF CCR9 ACTIVITY | Novartis Pharma AG (CH) | 2008-09-10 | — | — | EP | claimed |
| WO-2007071443-A1 | INHIBITORS OF CCR9 ACTIVITY | NOVARTIS AG (CH) | 2007-06-28 | — | — | WO | claimed |
| US-20080275114-A1 | Inhibitors of Ccr9 Activity | NOVARTIS AG (CH) | 2008-11-06 | — | — | US | disclosed |
| EP-1966131-A1 | INHIBITORS OF CCR9 ACTIVITY | Novartis Pharma AG (CH) | 2008-09-10 | — | — | EP | disclosed |
| WO-2007071443-A1 | INHIBITORS OF CCR9 ACTIVITY | NOVARTIS AG (CH) | 2007-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080275114-A1 | Inhibitors of Ccr9 Activity | CCR9, CCR1, CCR4 | HSD17B2 1512/4885SLC22A12 2675/4885CCR9 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.